Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-04-28

AUTHORS

Luciano Scopece, Enrico Franceschi, Giovanna Cavallo, Anna Paioli, Gabriele Paioli, Rosa Conforti, Emanuela Palmerini, Carlotta Berzioli, Federica Spagnolli, Roberta Degli Esposti, Lucio Crinò

ABSTRACT

BackgroundOligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.MethodsIn this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1–3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors.ResultsThirty-two patients were enrolled. Median age was 42 years (range 22–66); median ECOG PS was 0 (range 0–2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression–free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3–4 neutropenia in 5 (15.6%) patients.ConclusionsIn this trial CE regimen has shown relevant activity with a favourable safety profile. More... »

PAGES

299-305

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y

DOI

http://dx.doi.org/10.1007/s11060-006-9144-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021423420

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16645720


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carboplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etoposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Loss of Heterozygosity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scopece", 
        "givenName": "Luciano", 
        "id": "sg:person.0633145402.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633145402.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Franceschi", 
        "givenName": "Enrico", 
        "id": "sg:person.01073030767.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073030767.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cavallo", 
        "givenName": "Giovanna", 
        "id": "sg:person.01005014460.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005014460.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paioli", 
        "givenName": "Anna", 
        "id": "sg:person.01235471460.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paioli", 
        "givenName": "Gabriele", 
        "id": "sg:person.01167356260.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167356260.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Conforti", 
        "givenName": "Rosa", 
        "id": "sg:person.0675350014.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675350014.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmerini", 
        "givenName": "Emanuela", 
        "id": "sg:person.01210215667.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berzioli", 
        "givenName": "Carlotta", 
        "id": "sg:person.01122560745.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122560745.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spagnolli", 
        "givenName": "Federica", 
        "id": "sg:person.0756115375.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756115375.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Esposti", 
        "givenName": "Roberta Degli", 
        "id": "sg:person.0740317466.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740317466.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crin\u00f2", 
        "givenName": "Lucio", 
        "id": "sg:person.01306124223.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306124223.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf02390176", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047077907", 
          "https://doi.org/10.1007/bf02390176"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00177478", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040898461", 
          "https://doi.org/10.1007/bf00177478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008198089", 
          "https://doi.org/10.1038/sj.bjc.6602105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023147688", 
          "https://doi.org/10.1007/bf00686001"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-04-28", 
    "datePublishedReg": "2006-04-28", 
    "description": "BackgroundOligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.MethodsIn this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120\u00a0mg/m2 on days 1\u20133 every 28\u00a0days) in patients with recurrent/progressive oligodendroglial tumors.ResultsThirty-two patients were enrolled. Median age was 42\u00a0years (range 22\u201366); median ECOG PS was 0 (range 0\u20132); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8\u00a0months, progression\u2013free survivals at 6 and 12\u00a0months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3\u20134 neutropenia in 5 (15.6%) patients.ConclusionsIn this trial CE regimen has shown relevant activity with a favourable safety profile.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11060-006-9144-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "79"
      }
    ], 
    "keywords": [
      "CE regimen", 
      "response rate", 
      "oligodendroglial tumors", 
      "current chemotherapy regimens", 
      "median ECOG PS", 
      "progression-free survival", 
      "phase II trial", 
      "ResultsThirty-two patients", 
      "favorable safety profile", 
      "chemosensitive disease", 
      "ECOG PS", 
      "stable disease", 
      "chemotherapy regimens", 
      "etoposide regimen", 
      "II trial", 
      "median age", 
      "complete response", 
      "partial response", 
      "median time", 
      "active treatment", 
      "safety profile", 
      "anaplastic oligoastrocytoma", 
      "grade 3", 
      "toxicity profile", 
      "patients", 
      "regimen", 
      "tumors", 
      "carboplatin", 
      "oligoastrocytomas", 
      "disease", 
      "months", 
      "neutropenia", 
      "regimens", 
      "chemotherapy", 
      "MethodsIn", 
      "recurrent", 
      "trials", 
      "progression", 
      "response", 
      "efficacy", 
      "survival", 
      "age", 
      "treatment", 
      "ConclusionsIn", 
      "toxicity", 
      "overall results", 
      "rate", 
      "profile", 
      "relevant activities", 
      "years", 
      "setting", 
      "activity", 
      "time", 
      "results", 
      "PS"
    ], 
    "name": "Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors", 
    "pagination": "299-305", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021423420"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-006-9144-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16645720"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-006-9144-y", 
      "https://app.dimensions.ai/details/publication/pub.1021423420"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_425.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11060-006-9144-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      100 URIs      88 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-006-9144-y schema:about N005e604116cc4ca7b863425e56baca7f
2 N04d85311b07c4d6bb63acf862177fbd9
3 N483e0d769f0c453a98124f40b82ebbaa
4 N4bf62bd7210e42c7998b0a79f4839ded
5 N50b7ee277a074375898f07406a8bcdc4
6 N570906addc9749c7b80c873fde00eb08
7 N578c8d7ae6734659b34e82ddbacd48b3
8 N6a7e0fc198eb471e9b1487b1a101ecc4
9 N6b830241af8d46749e065ab964cd7c07
10 N6dec74abcd9f4cfaa2ada8ae6b09df37
11 N73a21d4bc5d541299bbe6088464b5f86
12 N832ef683b0b74e71b1ded296b5fe52af
13 Na5016a1e5e084c27a20635debf7441ae
14 Ndef83e0e4f9e4ca1b55fdeb241ab8bc6
15 Nef0fa2ceea7f4f3ea56e6df606023694
16 Nffb2ae8ef4aa4227b63967ba715f4816
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N14269cd3c43845bc81f539a6f5440cc6
20 schema:citation sg:pub.10.1007/bf00177478
21 sg:pub.10.1007/bf00686001
22 sg:pub.10.1007/bf02390176
23 sg:pub.10.1038/sj.bjc.6602105
24 schema:datePublished 2006-04-28
25 schema:datePublishedReg 2006-04-28
26 schema:description BackgroundOligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.MethodsIn this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1–3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors.ResultsThirty-two patients were enrolled. Median age was 42 years (range 22–66); median ECOG PS was 0 (range 0–2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression–free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3–4 neutropenia in 5 (15.6%) patients.ConclusionsIn this trial CE regimen has shown relevant activity with a favourable safety profile.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N2419eaaedaa9427a87bd5bb9cf45fbbd
30 N424d75706427460a8ae91957b8021726
31 sg:journal.1094205
32 schema:keywords CE regimen
33 ConclusionsIn
34 ECOG PS
35 II trial
36 MethodsIn
37 PS
38 ResultsThirty-two patients
39 active treatment
40 activity
41 age
42 anaplastic oligoastrocytoma
43 carboplatin
44 chemosensitive disease
45 chemotherapy
46 chemotherapy regimens
47 complete response
48 current chemotherapy regimens
49 disease
50 efficacy
51 etoposide regimen
52 favorable safety profile
53 grade 3
54 median ECOG PS
55 median age
56 median time
57 months
58 neutropenia
59 oligoastrocytomas
60 oligodendroglial tumors
61 overall results
62 partial response
63 patients
64 phase II trial
65 profile
66 progression
67 progression-free survival
68 rate
69 recurrent
70 regimen
71 regimens
72 relevant activities
73 response
74 response rate
75 results
76 safety profile
77 setting
78 stable disease
79 survival
80 time
81 toxicity
82 toxicity profile
83 treatment
84 trials
85 tumors
86 years
87 schema:name Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors
88 schema:pagination 299-305
89 schema:productId N615b65b7adb14468870490864ccb7a81
90 N9ffeb5ae7f4d4ff881da6a254dd7072b
91 Nbc797f0be6b24e99aaf89069e8237b3b
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021423420
93 https://doi.org/10.1007/s11060-006-9144-y
94 schema:sdDatePublished 2022-10-01T06:33
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nddb66f460ce7406d981a79331ebe0917
97 schema:url https://doi.org/10.1007/s11060-006-9144-y
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N005e604116cc4ca7b863425e56baca7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Etoposide
103 rdf:type schema:DefinedTerm
104 N04d85311b07c4d6bb63acf862177fbd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Middle Aged
106 rdf:type schema:DefinedTerm
107 N14269cd3c43845bc81f539a6f5440cc6 rdf:first sg:person.0633145402.85
108 rdf:rest N774bf8196dd44877a6984ffbf64e382a
109 N1746c3feca474269a9f056c251fc4afd rdf:first sg:person.01210215667.35
110 rdf:rest Nbe92844bd792462cbf9ea69e3dc252fd
111 N18d3a4a18e654c3ab8a2a9c855ab5b20 rdf:first sg:person.01235471460.73
112 rdf:rest Nafaca9616e1740d68106119bc82d8292
113 N2419eaaedaa9427a87bd5bb9cf45fbbd schema:issueNumber 3
114 rdf:type schema:PublicationIssue
115 N279042781eb548a7a1747c17c1b6c3f8 rdf:first sg:person.01005014460.46
116 rdf:rest N18d3a4a18e654c3ab8a2a9c855ab5b20
117 N424d75706427460a8ae91957b8021726 schema:volumeNumber 79
118 rdf:type schema:PublicationVolume
119 N483e0d769f0c453a98124f40b82ebbaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Survival Analysis
121 rdf:type schema:DefinedTerm
122 N4bf62bd7210e42c7998b0a79f4839ded schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Antineoplastic Combined Chemotherapy Protocols
124 rdf:type schema:DefinedTerm
125 N50b7ee277a074375898f07406a8bcdc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 N570906addc9749c7b80c873fde00eb08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Neoplasm Recurrence, Local
130 rdf:type schema:DefinedTerm
131 N578c8d7ae6734659b34e82ddbacd48b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Treatment Outcome
133 rdf:type schema:DefinedTerm
134 N615b65b7adb14468870490864ccb7a81 schema:name dimensions_id
135 schema:value pub.1021423420
136 rdf:type schema:PropertyValue
137 N6a7e0fc198eb471e9b1487b1a101ecc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Loss of Heterozygosity
139 rdf:type schema:DefinedTerm
140 N6b830241af8d46749e065ab964cd7c07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Female
142 rdf:type schema:DefinedTerm
143 N6dec74abcd9f4cfaa2ada8ae6b09df37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Disease-Free Survival
145 rdf:type schema:DefinedTerm
146 N73a21d4bc5d541299bbe6088464b5f86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Aged
148 rdf:type schema:DefinedTerm
149 N774bf8196dd44877a6984ffbf64e382a rdf:first sg:person.01073030767.87
150 rdf:rest N279042781eb548a7a1747c17c1b6c3f8
151 N832ef683b0b74e71b1ded296b5fe52af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Male
153 rdf:type schema:DefinedTerm
154 N838007d96a444fbc8b7619f945205748 rdf:first sg:person.0675350014.28
155 rdf:rest N1746c3feca474269a9f056c251fc4afd
156 N90e76d81d8f3442c9c5864fbfe465e59 rdf:first sg:person.0756115375.62
157 rdf:rest Na512699e93e74f24b0a3f0ffdbbd134d
158 N9ffeb5ae7f4d4ff881da6a254dd7072b schema:name pubmed_id
159 schema:value 16645720
160 rdf:type schema:PropertyValue
161 Na5016a1e5e084c27a20635debf7441ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Glioma
163 rdf:type schema:DefinedTerm
164 Na512699e93e74f24b0a3f0ffdbbd134d rdf:first sg:person.0740317466.20
165 rdf:rest Nb5fd3f0db2e5421f9f0d73181ab1ae7f
166 Nafaca9616e1740d68106119bc82d8292 rdf:first sg:person.01167356260.55
167 rdf:rest N838007d96a444fbc8b7619f945205748
168 Nb5fd3f0db2e5421f9f0d73181ab1ae7f rdf:first sg:person.01306124223.21
169 rdf:rest rdf:nil
170 Nbc797f0be6b24e99aaf89069e8237b3b schema:name doi
171 schema:value 10.1007/s11060-006-9144-y
172 rdf:type schema:PropertyValue
173 Nbe92844bd792462cbf9ea69e3dc252fd rdf:first sg:person.01122560745.27
174 rdf:rest N90e76d81d8f3442c9c5864fbfe465e59
175 Nddb66f460ce7406d981a79331ebe0917 schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 Ndef83e0e4f9e4ca1b55fdeb241ab8bc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Adult
179 rdf:type schema:DefinedTerm
180 Nef0fa2ceea7f4f3ea56e6df606023694 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Brain Neoplasms
182 rdf:type schema:DefinedTerm
183 Nffb2ae8ef4aa4227b63967ba715f4816 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Carboplatin
185 rdf:type schema:DefinedTerm
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
190 schema:name Clinical Sciences
191 rdf:type schema:DefinedTerm
192 sg:journal.1094205 schema:issn 0167-594X
193 1573-7373
194 schema:name Journal of Neuro-Oncology
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01005014460.46 schema:affiliation grid-institutes:grid.414405.0
198 schema:familyName Cavallo
199 schema:givenName Giovanna
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005014460.46
201 rdf:type schema:Person
202 sg:person.01073030767.87 schema:affiliation grid-institutes:grid.414405.0
203 schema:familyName Franceschi
204 schema:givenName Enrico
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073030767.87
206 rdf:type schema:Person
207 sg:person.01122560745.27 schema:affiliation grid-institutes:grid.414405.0
208 schema:familyName Berzioli
209 schema:givenName Carlotta
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122560745.27
211 rdf:type schema:Person
212 sg:person.01167356260.55 schema:affiliation grid-institutes:grid.414405.0
213 schema:familyName Paioli
214 schema:givenName Gabriele
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167356260.55
216 rdf:type schema:Person
217 sg:person.01210215667.35 schema:affiliation grid-institutes:grid.414405.0
218 schema:familyName Palmerini
219 schema:givenName Emanuela
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35
221 rdf:type schema:Person
222 sg:person.01235471460.73 schema:affiliation grid-institutes:grid.414405.0
223 schema:familyName Paioli
224 schema:givenName Anna
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73
226 rdf:type schema:Person
227 sg:person.01306124223.21 schema:affiliation grid-institutes:grid.414405.0
228 schema:familyName Crinò
229 schema:givenName Lucio
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306124223.21
231 rdf:type schema:Person
232 sg:person.0633145402.85 schema:affiliation grid-institutes:grid.414405.0
233 schema:familyName Scopece
234 schema:givenName Luciano
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633145402.85
236 rdf:type schema:Person
237 sg:person.0675350014.28 schema:affiliation grid-institutes:grid.414405.0
238 schema:familyName Conforti
239 schema:givenName Rosa
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675350014.28
241 rdf:type schema:Person
242 sg:person.0740317466.20 schema:affiliation grid-institutes:grid.414405.0
243 schema:familyName Esposti
244 schema:givenName Roberta Degli
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740317466.20
246 rdf:type schema:Person
247 sg:person.0756115375.62 schema:affiliation grid-institutes:grid.414405.0
248 schema:familyName Spagnolli
249 schema:givenName Federica
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756115375.62
251 rdf:type schema:Person
252 sg:pub.10.1007/bf00177478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040898461
253 https://doi.org/10.1007/bf00177478
254 rdf:type schema:CreativeWork
255 sg:pub.10.1007/bf00686001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023147688
256 https://doi.org/10.1007/bf00686001
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/bf02390176 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047077907
259 https://doi.org/10.1007/bf02390176
260 rdf:type schema:CreativeWork
261 sg:pub.10.1038/sj.bjc.6602105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008198089
262 https://doi.org/10.1038/sj.bjc.6602105
263 rdf:type schema:CreativeWork
264 grid-institutes:grid.414405.0 schema:alternateName Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy
265 schema:name Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...